Tolebrutinib also significantly lowered the annualized rate of new or enlarging T2 lesions compared with placebo (adjusted rate ratio 0.62, 95% 0.43-0.90, P=0.011).No significant difference was ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The ...

Tolebrutinib is an investigational, oral, brain-penetrant and bioactive Bruton's tyrosine kinase (BTK) inhibitor specifically designed to target smoldering neuroinflammation, a key driver of ...

The quest to mitigate disability progression in multiple sclerosis (MS) has long been hindered by our limited understanding ...

Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study Data presented at ECTRIMS show ...

Tolebrutinib is currently under review by the FDA. "If approved, the drug will likely require intensive monitoring of liver function enzymes during the first three months of therapy, ...

Tolebrutinib, a novel BTK inhibitor that targets neuroinflammation, slowed disability progression by 31% in nrSPMS, a phase 3 trial has shown. News & Perspective Tools & Reference CME/CE.

A clinical trial of tolebrutinib, an investigational oral Bruton’s tyrosine kinase inhibitor, demonstrated a 31% delay in the onset of six-month confirmed disability progression in patients with ...

Tolebrutinib also demonstrated other positive benefits, results show: Nearly twice as many patients taking the drug experienced improvements in their disability, 8.6% versus 4.5% with placebo.

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in ...

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton’s tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, ...

Paris, April 8, 2025.The New England Journal of Medicine (NEJM) published positive results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability progression in people with ...